drugset / Trial / NCT03526588

Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury in Infants With Congenital Diaphragmatic Hernia (CDH)

NCT03526588

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the use of autologous umbilical cord blood (UCB) mononuclear cells to mitigate hypoxic neurologic injury among infants with high-risk congenital diaphragmatic hernia (CDH).

Timeline

Start
2018-08-01
Primary completion
2022-07-01
Completion
2024-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous cord blood Cell therapy 6e+06 cells Intravenous